Which tacrolimus is better for black kidney transplant patients?
NCT ID NCT03841097
First seen Nov 01, 2025 · Last updated Jun 05, 2026 · Updated 34 times
Summary
This study looks at two different versions of the anti-rejection drug tacrolimus in African American kidney transplant recipients. One is taken once a day, the other twice a day. The goal is to see which one helps keep blood vessels healthier and works better overall. About 60 people will take part, and their blood vessel health will be checked over 12 to 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.